- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech High Growth Potential Companies
U.S. Pharmaceuticals & Biotech High Growth Potential Companies
Results
168
168 companies
Ascendis Pharma
Market Cap: US$8.6b
A biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally.
ASND
US$150.99
7D
5.8%
1Y
3.4%
Travere Therapeutics
Market Cap: US$1.3b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$14.50
7D
-3.3%
1Y
127.6%
Alnylam Pharmaceuticals
Market Cap: US$30.8b
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.
ALNY
US$237.77
7D
0.9%
1Y
60.1%
Zevra Therapeutics
Market Cap: US$373.4m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$6.90
7D
-2.0%
1Y
43.8%
AVITA Medical
Market Cap: US$227.9m
Operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.
RCEL
US$8.62
7D
14.9%
1Y
-12.8%
Axsome Therapeutics
Market Cap: US$4.8b
A biopharmaceutical company, engages in developing and delivering novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$98.06
7D
-0.8%
1Y
41.8%
TG Therapeutics
Market Cap: US$5.3b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$36.71
7D
-1.7%
1Y
159.3%
Arcutis Biotherapeutics
Market Cap: US$1.5b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$12.59
7D
-14.5%
1Y
23.4%
Evolus
Market Cap: US$606.6m
A performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.
EOLS
US$9.54
7D
-10.8%
1Y
-21.1%
Clene
Market Cap: US$26.0m
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
CLNN
US$3.03
7D
12.6%
1Y
-57.9%
Alvotech
Market Cap: US$2.5b
Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
ALVO
US$8.79
7D
3.4%
1Y
-28.2%
Blueprint Medicines
Market Cap: US$5.2b
A precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.
BPMC
US$80.84
7D
-1.0%
1Y
-7.3%
Legend Biotech
Market Cap: US$5.9b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$32.00
7D
-0.03%
1Y
-39.5%
ARS Pharmaceuticals
Market Cap: US$1.3b
A biopharmaceutical company, develops treatments for severe allergic reactions.
SPRY
US$14.05
7D
9.8%
1Y
55.8%
Madrigal Pharmaceuticals
Market Cap: US$7.0b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$317.15
7D
0.9%
1Y
34.1%
RenovoRx
Market Cap: US$28.2m
A clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$0.77
7D
-12.4%
1Y
-36.7%
Abeona Therapeutics
Market Cap: US$223.3m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$4.60
7D
1.8%
1Y
-39.1%
MeiraGTx Holdings
Market Cap: US$410.0m
A clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases.
MGTX
US$5.20
7D
-8.5%
1Y
-6.5%
Exelixis
Market Cap: US$9.9b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$35.31
7D
2.1%
1Y
54.8%
Sarepta Therapeutics
Market Cap: US$5.0b
A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
SRPT
US$51.03
7D
-6.2%
1Y
-58.5%
Checkpoint Therapeutics
Market Cap: US$334.2m
A clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally.
CKPT
US$3.99
7D
-0.5%
1Y
124.2%
Soleno Therapeutics
Market Cap: US$3.1b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$67.23
7D
-0.4%
1Y
81.0%
OS Therapies
Market Cap: US$27.1m
A clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
OSTX
US$1.25
7D
-10.7%
1Y
n/a
Nutriband
Market Cap: US$52.4m
Develops a portfolio of transdermal pharmaceutical products.
NTRB
US$4.72
7D
-12.6%
1Y
7.0%
Silence Therapeutics
Market Cap: US$121.4m
A biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
SLN
US$2.57
7D
-1.5%
1Y
-88.4%
Corcept Therapeutics
Market Cap: US$7.2b
Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$68.62
7D
-7.8%
1Y
191.9%
SpringWorks Therapeutics
Market Cap: US$2.7b
A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer.
SWTX
US$36.47
7D
-6.7%
1Y
-14.7%
Vanda Pharmaceuticals
Market Cap: US$240.8m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$4.13
7D
-0.2%
1Y
0.2%
ACADIA Pharmaceuticals
Market Cap: US$2.4b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$14.58
7D
-5.2%
1Y
-14.9%
UroGen Pharma
Market Cap: US$466.5m
Engages in the development and commercialization of solutions for urothelial and specialty cancers.
URGN
US$10.12
7D
-1.3%
1Y
-33.0%
Evoke Pharma
Market Cap: US$4.6m
Operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
EVOK
US$2.20
7D
-2.2%
1Y
-64.1%
Tenaya Therapeutics
Market Cap: US$79.6m
A clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
TNYA
US$0.49
7D
-1.2%
1Y
-88.9%
Aldeyra Therapeutics
Market Cap: US$114.0m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$1.91
7D
1.1%
1Y
-55.1%
Capricor Therapeutics
Market Cap: US$424.3m
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$9.29
7D
2.5%
1Y
48.6%
Eton Pharmaceuticals
Market Cap: US$333.9m
A specialty pharmaceutical company, focuses on developing, and commercializing pharmaceutical products for rare diseases.
ETON
US$12.45
7D
5.2%
1Y
264.0%
CorMedix
Market Cap: US$450.4m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$6.91
7D
17.9%
1Y
18.3%